Scientists at UW Medicine and the NIH have created an experimental flu vaccine that spurs broad immunity in animal trials
Researchers have developed experimental flu shots that protect animals from a wide variety of seasonal and pandemic influenza strains. The vaccine product is currently being advanced toward clinical testing. If proven safe and effective, these next-generation influenza vaccines may replace current seasonal options by providing protection against many more strains that current vaccines do not adequately cover.
A study detailing how the new flu vaccines were designed and how they protect mice, ferrets, and nonhuman primates appears in the March 24 edition of the journal Nature. This work was led by researchers at the University of Washington School of Medicine and the Vaccine Research Center part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
Influenza virus causes an estimated 290,000–650,000 deaths per year. Available flu vaccines, which need to be taken seasonally, often fail to protect against many circulating flu strains that cause illness, and the threat of another influenza pandemic looms.
“Most flu shots available today are quadrivalent, meaning they are made from four different flu strains. Each year, the World Health Organization makes a bet on which four strains will be most prevalent, but those predictions can be more or less accurate. This is why we often end up with ‘mismatched’ flu shots that are still helpful but only partially effective,” said lead author Daniel Ellis, a research scientist in the laboratory of Neil King. King is an assistant professor of biochemistry at the UW School of Medicine and a researcher at the Institute for Protein Design at UW Medicine.
To create improved influenza vaccines, the team attached hemagglutinin proteins from four different influenza viruses to custom-made protein nanoparticles. This approach enabled an unprecedented level of control over the molecular configuration of the resulting vaccine and yielded an improved immune response compared to conventional flu shots. The new nanoparticle vaccines, which contain the same four hemagglutinin proteins of commercially available quadrivalent influenza vaccines, elicited neutralizing antibody responses to vaccine-matched strains that were equivalent or superior to the commercial vaccines in mice, ferrets, and nonhuman primates. The nanoparticle vaccines—but not the commercial vaccines —also induced protective antibody responses to viruses not contained in the vaccine formulation. These include avian influenza viruses H5N1 and H7N9, which are considered pandemic threats.
The responses that our vaccine gives against strain-matched viruses are really strong, and the additional coverage we saw against mismatched strains could lower the risk of a bad flu season,” said Ellis.
Original Article: Nanoparticle flu shot blocks seasonal and pandemic strains
More from: University of Washington School of Medicine | National Institutes of Health
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Experimental flu vaccine
- Swine Flu News
Nov. 25, 2022 — An experimental mRNA-based vaccine against all 20 known subtypes of influenza virus provided broad protection from otherwise lethal flu strains in ... Flu Shots Can Protect ...
- New strategy could lead to universal, long-lasting flu shot
An experimental influenza vaccine carrying more than 80,000 variations of hemagglutinin antigens caused the immune system of mice and ferrets to respond more strongly to less variable portions of the ...
- Experimental Proactive Vaccine Protects Mice Against Known Coronaviruses And Those To Come
R esearchers working on a near-universal coronavirus vaccine that could stop outbreaks before they get started have reported success in mice. The vaccine confers immunity against the original SARS ...
- New vaccine approach shows promise in targeting less variable region of influenza virus
feature=shared) Influenza strains are referred to by a shorthand code ... In lab tests and animals, the experimental vaccine caused the immune system to respond more strongly to stalk regions because ...
- Moderna expects CDC to view its RSV vaccine as equal to rival shots
Moderna said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC) advisers to recommend the company's respiratory syncytial virus (RSV) vaccine be considered equal to rival ...
Go deeper with Google Headlines on:
Experimental flu vaccine
[google_news title=”” keyword=”experimental flu vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Nanoparticle flu vaccine
- New strategy could lead to universal, long-lasting flu shot
An experimental influenza vaccine carrying more than 80,000 variations of hemagglutinin antigens caused the immune system of mice and ferrets to respond more strongly to less variable portions of the ...
- New influenza vaccine strategies aim to enhance protection with T-cell responses
A recent review highlights the need for innovative influenza vaccines that combine T-cell and antibody responses to enhance protection across multiple strains and seasons.
- New mRNA Vaccines in Development for Cancer and Infections
Prelog also discussed personalized vaccines for cancer immunotherapy. Personalized mRNA vaccines are tailored to the patient's genetic characteristics and antigens. They could be used in cancer ...
- Influenza News
Mar. 1, 2024 — Researchers have identified antibodies targeting a hard-to-spot region of the influenza virus, shedding light on the relatively unexplored 'dark side' of the neuraminidase (NA ...
- Universal Flu Vaccine May No Longer Be a Long Shot
A schematic diagram of the influenza virus, showing the surface proteins hemagglutinin (blue, peanut shaped) and neuraminidase (red, flower shaped), to which antibodies attach during an immune ...
Go deeper with Google Headlines on:
Nanoparticle flu vaccine
[google_news title=”” keyword=”nanoparticle flu vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]